Volume 66, Issue 6, Pages (December 2004)

Slides:



Advertisements
Similar presentations
Volume 67, Issue 2, Pages (February 2005)
Advertisements

Volume 65, Issue 4, Pages (April 2004)
Volume 88, Issue 5, Pages (November 2015)
Volume 78, Issue 3, Pages (August 2010)
Canonical Wnt/β-catenin signaling mediates transforming growth factor-β1-driven podocyte injury and proteinuria  Dan Wang, Chunsun Dai, Yingjian Li, Youhua.
Rapamycin is an effective inhibitor of human renal cancer metastasis1
Volume 81, Issue 9, Pages (May 2012)
Volume 56, Issue 4, Pages (October 1999)
Volume 78, Issue 4, Pages (August 2010)
Volume 66, Issue 3, Pages (September 2004)
Volume 61, Issue 2, Pages (February 2002)
Molecular Therapy - Nucleic Acids
Volume 61, Issue 4, Pages (April 2002)
Volume 80, Issue 4, Pages (August 2011)
Volume 55, Issue 2, Pages (February 1999)
C.B. Marshall, J.W. Pippin, R.D. Krofft, S.J. Shankland 
Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis  Y. Huang, W.A. Border, D.A. Lawrence, N.A.
Volume 64, Issue 1, Pages (July 2003)
Volume 67, Issue 5, Pages (May 2005)
Volume 83, Issue 5, Pages (May 2013)
Volume 66, Issue 6, Pages (December 2004)
Volume 63, Issue 4, Pages (April 2003)
TGF-β isoforms in renal fibrogenesis
Volume 67, Issue 4, Pages (April 2005)
Volume 63, Issue 1, Pages (January 2003)
Volume 66, Issue 5, Pages (November 2004)
Volume 56, Issue 6, Pages (December 1999)
Volume 64, Issue 5, Pages (November 2003)
Volume 68, Issue 1, Pages (July 2005)
Volume 87, Issue 2, Pages (February 2015)
Volume 64, Issue 2, Pages (August 2003)
Volume 56, Issue 3, Pages (September 1999)
Volume 62, Issue 5, Pages (November 2002)
PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice
Volume 68, Issue 2, Pages (August 2005)
Isotretinoin alleviates renal damage in rat chronic glomerulonephritis
Volume 64, Issue 4, Pages (October 2003)
Volume 67, Issue 5, Pages (May 2005)
Gene transfer of truncated IκBα prevents tubulointerstitial injury
Volume 60, Issue 6, Pages (December 2001)
Volume 67, Issue 2, Pages (February 2005)
Volume 53, Issue 5, Pages (May 1998)
Volume 58, Issue 1, Pages (July 2000)
Volume 61, Issue 5, Pages (May 2002)
Renoprotective role of the vitamin D receptor in diabetic nephropathy
Volume 66, Issue 3, Pages (September 2004)
Volume 70, Issue 10, Pages (November 2006)
Volume 61, Issue 6, Pages (June 2002)
Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis  J. Mahmood, F. Khan, S. Okada,
Volume 62, Issue 3, Pages (September 2002)
Volume 62, Issue 5, Pages (November 2002)
Volume 65, Issue 1, Pages (January 2004)
Volume 57, Issue 1, Pages (January 2000)
Volume 66, Issue 4, Pages (October 2004)
Volume 64, Issue 3, Pages (September 2003)
Volume 61, Issue 6, Pages (June 2002)
Nitric oxide and glomerulonephritis
Volume 60, Issue 5, Pages (November 2001)
Volume 65, Issue 6, Pages (June 2004)
Volume 67, Issue 6, Pages (June 2005)
Prasun K. Datta, Elias A. Lianos  Kidney International 
Volume 63, Issue 1, Pages (January 2003)
Volume 58, Issue 3, Pages (September 2000)
Volume 67, Issue 6, Pages (June 2005)
Jens Gaedeke, Nancy A. Noble, Wayne A. Border  Kidney International 
IL-1β induces VEGF, independently of PGE2 induction, mainly through the PI3-K/mTOR pathway in renal mesangial cells  D. Solà-Villà, M. Camacho, R. Solà,
T-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis  Masashi Haraguchi, Wayne A. Border, Yufeng Huang,
Volume 61, Issue 3, Pages (March 2002)
Volume 55, Issue 4, Pages (April 1999)
Volume 56, Issue 4, Pages (October 1999)
Presentation transcript:

Volume 66, Issue 6, Pages 2224-2236 (December 2004) Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis  Harm Peters, Yingrui Wang, Tanja Loof, Sebastian Martini, Susanne Kron, Stephanie Krämer, Hans-H Neumayer  Kidney International  Volume 66, Issue 6, Pages 2224-2236 (December 2004) DOI: 10.1111/j.1523-1755.2004.66012.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Tail bleeding time (A) and systolic blood pressure (B) in rats with induced anti-thy1 glomerulonephritis (GN). Shown are the effects of the pharmacologic soluble guanylate cyclase stimulator Bay 41-2272. Normal control animals (control) were injected with phosphate-buffered saline (PBS). Anti-thy1 glomerulonephritis was induced by injection of OX-7 antibody. Bleeding was induced by a standard tail incision (10 mm long and 1 mm deep) in anesthetized animals. Blood pressure was measured in conscious animals using a tail cuff method. **P < 0.01 vs. GN. Kidney International 2004 66, 2224-2236DOI: (10.1111/j.1523-1755.2004.66012.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 2 Plasma cyclic guanosine monophosphate (cGMP) levels in rats with induced anti-thy1 glomerulonephritis (GN). Shown are the effects of the pharmacologic soluble guanylate cyclase stimulator Bay 41-2272. Normal control animals (control) were injected with phosphate-buffered saline (PBS). Anti-thy1 glomerulonephritis was induced by injection of OX-7 antibody. *P < 0.05 and **P < 0.01 vs. control; #P < 0.05 vs. GN. Kidney International 2004 66, 2224-2236DOI: (10.1111/j.1523-1755.2004.66012.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 3 Indices of glomerular mesangial cell lysis in rats 1 day after induction of acute anti-thy1 glomerulonephritis (GN) (protocol 1, injury). Shown are glomerular nuclei count (A) indicating mesangial cell lysis, basal (B), and lipopolysaccharide (LPS)-stimulated nitric oxide (NO) production (C) as well as inducible nitric oxide synthase (iNOS) mRNA expression (D). The rats were treated with the guanylate cyclase stimulator Bay 41-2272 from day 6 before disease induction until sacrifice. Anti-thy1 glomerulonephritis was induced by injection of OX-7 antibody. Normal control animals (control) were injected with phosphate-buffered saline (PBS). **P < 0.01 and ***P < 0.001 vs. control. Kidney International 2004 66, 2224-2236DOI: (10.1111/j.1523-1755.2004.66012.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 4 Glomerular mRNA expression of endothelial nitric oxide synthase (eNOS) (A), α1 soluble guanylate cyclyse (alpha1 sGC) (B), and β1 soluble guanylate cyclase (beta1 sGC) (C) in rats 1 day after induction of acute anti-thy1 glomerulonephritis (GN) (protocol 1, injury). The rats were treated with the guanylate cyclase stimulator Bay 41-2272 from day 6 before disease induction until sacrifice. Anti-thy1 glomerulonephritis was induced by injection of OX-7 antibody. Normal control animals (control) were injected with phosphate-buffered saline (PBS). mRNA was analyzed by a real-time polymerase chain reaction (PCR) method using gyceraldehyde-3-phosphate dehydrogenase (GAPDH) as housekeeping gene. mRNA expression is shown as a percentage of the normal control group. ***P < 0.001 vs. control. Kidney International 2004 66, 2224-2236DOI: (10.1111/j.1523-1755.2004.66012.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 5 Basal (A) and nitric oxid-stimulated (B) glomerular cyclic guanosine monophosphate (cGMP) synthesis in rats 1 day after induction of acute anti-thy1 glomerulonephritis (GN) (protocol 1, injury). The rats were treated with the guanylate cyclase stimulator Bay 41-2272 from day 6 before disease induction until sacrifice. Anti-thy1 glomerulonephritis was induced by injection of OX-7 antibody. Normal control animals (control) were injected with phosphate-buffered saline (PBS). cGMP generation was measured by enzyme-linked immunosorbent assay (ELISA) in glomeruli harvested from individual animals in the presence or absence of the nitric oxide donor DEA/NO. **P < 0.01 vs. control. Kidney International 2004 66, 2224-2236DOI: (10.1111/j.1523-1755.2004.66012.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 6 Urinary protein excretion 7 days after induction of acute anti-thy1 glomerulonephritis (GN) (protocol 2, repair). Treatment with Bay 41-2272 was started 24 hours after disease induction. Urine was collected for 24 hours using metabolic cages. *P < 0.05 vs. GN. Kidney International 2004 66, 2224-2236DOI: (10.1111/j.1523-1755.2004.66012.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 7 Markers of glomerular matrix expansion 7 days after induction of acute anti-thy1 glomerulonephritis (GN) (protocol 2, repair). Shown are the glomerular matrix accumulation (A) and glomerular production of transforming growth factor (TGF)-β1 (B), fibronectin (C), and plaminogen-activator inhibitor (PAI)-1 (D). Controls received phosphate-buffered saline (PBS) (control). Treatment with Bay 41-2272 was started 24 hours after disease induction. Matrix expansion was scored on periodic acid-Schiff (PAS)-stained slides. Glomeruli were harvested from individual animals and cultured at a density of 2000 per mL for 48 hours. *P < 0.05 and **P < 0.01 vs. GN. Kidney International 2004 66, 2224-2236DOI: (10.1111/j.1523-1755.2004.66012.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 8 mRNA expression of endothelial nitric oxide synthase (eNOS) (A) and α1 soluble guanylate cyclase (alpha1 sGC) (B), and β1 soluble guanylate cyclyase (beta1 sGC) (C) 7 days after induction of acute anti-thy1 glomerulonephritis (GN) (protocol 2, repair). Treatment with Bay 41-2272 was started 24 hours after disease induction. Anti-thy1 glomerulonephritis was induced by injection of OX-7 antibody. Normal control animals (control) were injected with phosphate-buffered saline (PBS). mRNA was analyzed by a real-time polymerase chain reaction (PCR) method using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as housekeeping gene. mRNA expression is shown as a percentage of the normal control group. ***P < 0.001 vs. control; #P < 0.05 vs. GN. Kidney International 2004 66, 2224-2236DOI: (10.1111/j.1523-1755.2004.66012.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 9 Basal (A) and nitric oxide-stimulated (B) glomerular cyclic guanosine monophosphate (cGMP) synthesis 7 days after induction of acute anti-thy1 glomerulonephritis (GN) (protocol 2, repair). Treatment with Bay 41-2272 was started 24 hours after disease induction. Anti-thy1 glomerulonephritis was induced by injection of OX-7 antibody. Normal control animals (control) were injected with phosphate-buffered saline (PBS). cGMP generation was measured by enzyme-linked immunosorbent assay (ELISA) in glomeruli harvested from individual animals in the presence of absence of the nitric oxide donor DEA/NO. **P < 0.01 and ***P < 0.001 vs. control; #P < 0.05 vs. GN. Kidney International 2004 66, 2224-2236DOI: (10.1111/j.1523-1755.2004.66012.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 10 Effects of the soluble guanylate cyclyase stimulator Bay 41-2272 on (A) and nephritic (B) glomerular normal transforming growth factor (TGF)-β1 production in vitro (protocol 2, repair). Glomeruli were harvested from individual animals (normal nonnephritic and day 7-nephritic animals) and cultured at a density of 2000 per mL for 48 hours in the presence of the indicated concentrations of Bay 41-2272. Glomeruli without Bay 41-2272 served as control. *P < 0.05 vs. control. Kidney International 2004 66, 2224-2236DOI: (10.1111/j.1523-1755.2004.66012.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 11 Glomerular p-selectin mRNA expression (A) and macrophage infiltration (B) 7 days after induction of acute anti-thy1 glomerulonephritis (GN) (protocol 2, repair). Treatment with Bay 41-2272 was started 24 hours after disease induction. Anti-thy1 glomerulonephritis was induced by injection of OX-7 antibody. Normal control animals (control) were injected with phosphate-buffered saline (PBS). P-selectin mRNA was analyzed by a real-time polymerase chain reaction (PCR) method using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as housekeeping gene and is shown as a percentage of the normal control group. Glomerular macrophage infiltration is expressed as number of ED1 antibody-positive cells per glomerular cross-section. *P < 0.05 vs. GN. Kidney International 2004 66, 2224-2236DOI: (10.1111/j.1523-1755.2004.66012.x) Copyright © 2004 International Society of Nephrology Terms and Conditions